How OPMD progresses in people in Israel
Official title: Natural History of Oculo-Pharyngeal Muscular Dystrophy (OPMD) - Israel National OPMD Registry
Run by Sheba Medical Center · NCT07146256 · Data updated 2026-11-12
This project will track adults with OPMD or suggestive symptoms in Israel over time to see how swallowing, eyelid droop, muscle strength, breathing, thinking, and oral health change.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Sheba Medical Center Government |
| Locations | 1 site (Ramat Gan) |
| Status | Recruiting |
| Started | February 1, 2022 |
| Main results expected | January 2030 |
| Study ends | January 2030 |
| Registry record updated | August 28, 2025 |
| Trial ID | NCT07146256 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age 18 or older) with a clinical diagnosis of OPMD or with signs or symptoms suggestive of OPMD are ideal candidates for participation.
✕Probably not a fit
This observational project does not provide experimental treatments, so children under 18, pregnant people, or those seeking immediate therapeutic benefit are unlikely to gain direct treatment effects from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an open, prospective, multidisciplinary observational registry enrolling people with Oculopharyngeal Muscular Dystrophy (OPMD) or suggestive signs. Participants undergo neurological and neurocognitive exams and clinical assessments of swallowing, eyelid ptosis, respiratory muscle function, and oral health at planned visits. Clinical teams collect standardized measures to document symptom onset, progression, and variability across disease stages. The goal is to characterize the natural history of OPMD in the Israeli population to inform care and future trials.
Why it matters
Potential benefit: If successful, the registry could improve prediction of disease course, guide clinical care, and help design future treatment trials for people with OPMD.
How similar studies have gone: Natural-history registries and observational cohorts elsewhere have improved understanding of OPMD progression, but data remain limited and this registry provides focused information for the Israeli population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with clinical diagnosis of OPMD or patients with signs /symptoms suggestive of OPMD Exclusion Criteria: * Age \<18 years and Pregnancy
Where it's running
-
Sheba Medical Center
Ramat Gan, Israel Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registry for patients with rare diseases
This study is creating a central registry for people with rare diseases to help connect them with researchers and improve treatments.
-
Tele-diabetes remote monitoring for kids with type 1 diabetes
This study tests a tele-diabetes remote system that uses WhatsApp alerts to help children and teens manage their type 1 diabetes at home.
-
Ex Vivo Drug Response Testing in Lung Adenocarcinoma with Malignant Pleural Effusions
This study tests whether the way cancer cells from pleural effusions respond to drugs outside the body can predict how patients will respond to treatment.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
-
Using a portable VR headset to measure pupil reactions for diagnosing and monitoring head injury
This research tests whether a VR headset that flashes brief, gentle colored lights can detect and track traumatic brain injury by measuring how the pupil responds in people with TBI, similar non-TBI trauma patients, and healthy adults.
-
Group versus individual MDMA-assisted therapy for PTSD related to the October 7, 2023 events
The study will see if group-based MDMA-assisted therapy works as well and is as safe as individual MDMA-assisted therapy for adults diagnosed with PTSD after October 7, 2023.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.